REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.04
−1.65%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.6x
Market Cap
$1.42B
MomentumView details →
1D Return
−1.65%
YTD Return
+54.42%
RSI (14)
56.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.6x
Market Cap
$1.42B
RSI (14)
56.4
MomentumView details →
1D Return
−1.65%
YTD Return
+54.42%
SummaryUpdated Jun 1, 2026
Replimune Group, Inc. (NASDAQ:REPL) is a clinical-stage biotechnology company founded in 2015 and headquartered in Woburn, Massachusetts. The company went public in July 2018 and specializes in developing oncolytic immuno-gene therapies, a cutting-edge approach to cancer treatment that uses genetically modified viruses to selectively target and destroy cancer cells while simultaneously activating the patient's immune system. Replimune is currently preparing for the potential commercial launch of its lead product candidate RP1, which has received breakthrough therapy designation from the FDA and has a Prescription Drug User Fee Act (PDUFA) date of July 22, 2025.
Similar companies
Latest newsMore news →
Replimune Group announced the appointment of Michelle DiNapoli as Chief Commercial Officer.21d agoReplimune Group reported a net loss of $69.8 million for Q1 2027, compared to a net loss of $86.7 million in Q1 2026, with diluted EPS of -$0.72.22d agoReplimune Group's stock gapped up at market open on Monday after JPMorgan Chase raised its price target from $17.00 to $20.00, with the stock opening at $12.64 after closing at $12.06.25d ago